Halia Therapeutics Announces Key Leadership Additions and Organizational Growth

Halia Therapeutics Strengthens Leadership and Clinical Operations Team

Halia Therapeutics, a leader in the biopharmaceutical industry, has made significant strides in its leadership and clinical operations by welcoming new executives and promoting existing team members. This strategic move is aimed at bolstering the company’s capabilities as it continues to develop groundbreaking treatments for chronic inflammation and related disorders.

On January 6, 2025, Halia announced that Gary Sabin, an experienced figure in business development and corporate governance, has joined the Board of Directors. His extensive expertise in strategic growth will provide Halia with the insights and connections needed to navigate the complex biopharmaceutical landscape. His arrival marks a crucial point in Halia’s journey toward furthering innovation and expanding its influence in the market.

In addition to Sabin’s appointment, the company has promoted Dr. Margit Janat-Amsbury, MD, PhD, to Chief Scientific Officer. Dr. Janat-Amsbury has been an integral part of Halia’s success, playing a central role in advancing the company's pipeline. With her new title, she will oversee the scientific vision of Halia, ensuring that the development of new therapies aligns with the organization's mission to enhance patient outcomes. Her expertise and leadership are expected to drive the clinical success of Halia’s flagship programs which target inflammation and metabolic disorders.

Moreover, Halia is welcoming Tracey Clayton as the Vice President of Program Management and Clinical Operations, alongside Stephen Anthony, DO, who joins as Senior Vice President of Clinical Development. Both Clayton and Anthony possess invaluable decades of experience in clinical trial execution and operational excellence. Clayton, previously an Executive Director at Sumitomo Pharma, is well-versed in global clinical trial management which will be essential for navigating Halia’s extensive clinical pipeline. Anthony brings a wealth of knowledge in regulatory compliance and operational strategy, skills that are crucial for overseeing clinical development processes. The addition of these skilled professionals is poised to play a pivotal role in advancing Halia's robust clinical offerings.

Dr. David J. Bearss, the President and CEO of Halia Therapeutics, expressed optimism regarding the new appointments, stating, "Today marks a significant milestone in Halia’s journey. The contributions made by Gary Sabin, Tracey Clayton, and Stephen Anthony will enhance our capabilities as we pursue our strategic objectives. Additionally, Margit’s promotion reflects her exceptional contributions to our science and innovation." These leadership changes are a testament to Halia’s commitment to transforming lives through the creation of impactful therapies that target chronic inflammatory conditions.

Halia Therapeutics is dedicated to advancing its groundbreaking therapies and addressing the needs of patients worldwide. With its focus on innovative solutions, the company is committed to providing substantial advancements in the treatment of chronic inflammatory disorders and neurodegenerative diseases. Among its key programs is HT-6184, a novel NEK7/NLRP3 inhibitor, which recently completed a Phase I study. Halia is also conducting Phase II trials for HT-6184 focusing on lower-risk myelodysplastic syndromes (LR-MDS) and evaluating its effects on inflammation and pain post-diagnostic procedures.

As the company moves forward, the newly strengthened leadership team is expected to guide Halia Therapeutics towards a promising future of enhanced therapeutic options for patients suffering from inflammation-related disorders. To stay updated on Halia’s groundbreaking research and developments, interested individuals are encouraged to visit their website at www.haliatx.com or connect with them on LinkedIn and Twitter (X).

About Halia Therapeutics, Inc.
Founded in Lehi, Utah, Halia Therapeutics is pioneering a pipeline of innovative therapeutics aimed at improving the lives of patients affected by chronic inflammatory and neurodegenerative diseases. The company is committed to delivering impactful solutions that address significant medical needs in this vital healthcare space.